Skip to main content

Table 4 Relationship between clinical characteristics and SIRI of NPC patients with negative EBV DNA in training and validation cohorts

From: Prognostic value of systemic inflammation response index in nasopharyngeal carcinoma with negative Epstein-Barr virus DNA

Variables

Training cohort (n = 170)

Validation cohort (n = 155)

SIRI

p

SIRI

p

 ≤ 1.12

 > 1.12

 ≤ 1.12

 > 1.12

Gender, No.(%)

  

0.620

  

0.038

 male

81 (64.8)

31 (68.9)

 

78 (70.9)

39 (86.7)

 

 female

44 (35.2)

14 (31.3)

 

32 (29.1)

6 (13.3)

 

Age, No.(%)

  

0.293

  

0.520

 ≤ 55

101 (80.8)

33 (73.3)

 

88 (80.0)

38 (84.4)

 

  > 55

24 (19.2)

12 (26.7)

 

22 (20.0)

7 (15.6)

 

Smoke

  

0.974

  

0.037

 no

83 (66.4)

30 (66.7)

 

69 (62.7)

20 (44.4)

 

 yes

42 (33.6)

15 (33.3)

 

41 (37.3)

25 (55.6)

 

AJCC stage (8th), No.(%)

  

0.037

  

0.059

 I-II

43 (34.4)

8 (17.8)

 

39 (35.5)

9 (20.0)

 

 III-IVb

82 (65.6)

37 (82.2)

 

71 (64.5)

36 (80.0)

 

Tumor classification, No.(%)

  

0.010

  

0.622

 T1-T2

61 (48.8)

12 (26.7)

 

61 (55.5)

23 (51.1)

 

 T3-T4

64 (51.2)

33 (73.3)

 

49 (44.5)

22 (48.9)

 

Node classification, No.(%)

  

0.113

  

0.081

 N0-N1

70 (56.0)

19 (42.2)

 

61 (55.5)

18 (40.0)

 

 N2-N3

55 (44.0)

26 (57.8)

 

49 (44.5)

27 (60.0)

 

Metastasis, No.(%)

  

0.656

  

0.498

 Non-metastasis

121 (96.8)

43 (95.6)

 

109 (99.1)

44 (97.8)

 

 Metastasis

4 (3.2)

2 (4.4)

 

1 (0.9)

1 (2.2)

 
  1. EBV DNA Epstein-Barr virus DNA, AJCC American Joint Committee on Cancer, SIRI Systemic inflammation response index